The Efficacy of Different Bupivacaine Concentrations in Pediatric Patients Undergoing Transversus Abdominis Plane Block
Transversus Abdominis Plane (TAP) Block With Different Bupivacaine Concentrations in Pediatric Patients Undergoing Unilateral Inguinal Hernia Repair Surgery: A Prospective Randomised Double-Blinded Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- American Society of Anesthesiologists (ASA) status I/II
- Children between 1 to 8 years of age
- Patients undergoing unilateral inguinal hernia repair surgery
Exclusion Criteria:
- Denial of parents
- Patients who are allergic to local anesthetics
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: TAP block with 1 mg.kg-1 bupivacaine 0.25%
Patients had 1 mg.kg-1 bupivacaine 0.25% with US-guided TAP block
|
Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
Other Names:
|
|
ACTIVE_COMPARATOR: TAP block with 1 mg.kg-1 bupivacaine 0.125%
Patients had 1 mg.kg-1 bupivacaine 0.125% with US-guided TAP block
|
Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
FLACC pediatric pain scores
Time Frame: up to 24 hours
|
It corporates five categories of behavior, each scored on 0-2 point scale so that total score ranges from 0-10.
|
up to 24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total analgesic requirement
Time Frame: up to 24 hours
|
Tramadol
|
up to 24 hours
|
|
First analgesic requirement time
Time Frame: up to 24 hours
|
Duration of postoperative analgesia
|
up to 24 hours
|
|
Incidence of side effects
Time Frame: up to 24 hours
|
Nausea, vomiting, respiratory depression
|
up to 24 hours
|
|
The length of hospital stay
Time Frame: up to 24 hours
|
Hospitalisation hours
|
up to 24 hours
|
|
Incidence of complications
Time Frame: up to first week.
|
Hemotoma, infection
|
up to first week.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Meltem Savran Karadeniz, Assoc. Prof, Istanbul University
- Study Chair: Emine Aysu Salviz, Assoc. Prof, Istanbul University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2016/1281
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.